Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Omslag van het boek

2012 | OriginalPaper | Hoofdstuk

Voeding bij neuromusculaire aandoeningen

(september 2011)

Auteur : J.C. Wijnen

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Neuromusculaire aandoeningen, ofwel spierziekten, omvatten een groot aantal ziekten met verscheidenheid in oorzaak, symptomen en verloop. De meeste ziekten zijn zeldzaam, progressief en de multidisciplinaire behandeling is voornamelijk symptomatisch. De aard en ernst van voedingsgerelateerde problemen wordt duidelijk gemaakt aan de hand van drie ziektebeelden: amyotrofische laterale sclerose, myotone dystrofie en Duchenne spierdystrofie. De specifieke aspecten van dysfagie, motiliteitsstoornissen, voedingsstoma, ademhalingsinsufficiëntie en secundaire problematiek op de voedingstoestand wordt nader uitgewerkt. DXA-scans en impedantiemetingen geven inzicht in de lichaamssamenstelling en energiebehoefte. Kerndoelen van de diëtistische behandeling zijn het verbeteren/ behouden van een goede voedingstoestand en de groei evenals het verminderen van symptomen bij dysfagie en gastrointestinale stoornissen.
Literatuur
Abdelnour-Mallet M, e.a. Safety of home parenteral nutrition in patients with amyotrophic lateral sclerosis: a French national survey. Amyotroph Lateral Scler 2011; 12(3): 178–84.
Aitkens S, e.a. Metabolic syndrome in neuromuscular disease. Archives Phys Med Rehab 2005; 86(5): 1030–1036.
Aloysius A, e.a. Swallowing difficulties in Duchenne muscular dystrophy: indications for feeding assessment and outcome of videofluroscopic swallow studies. Eur J of Paed Neur 2008; 12(3): 239–245.
Ambrosino N, Clini E. Long-term mechanical ventilation and nutrition. Res Med 2004; 98: 413–420.
Ambrosino N, Carpenè N, Gherardi M. Chronic respiratory care for neuromuscular diseases in adults. Eur Resp J 2009; 34: 444–451.
Amiot A, e.a. Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction. Gastroent 2009; 137: 101–109.
Antonucci A, e.a. Chronic intestinal pseudo-obstruction. World J Gastroent 2008; 14(19): 2953–2961.
Bach JR, e.a. Open gastrostomy for noninvasive ventilation users with neuromuscular disease. Am J Phys Med Rehab 2010; 89(1): 1–6.
Bedlack RS. Amyotrophic lateral sclerosis: current practice and future treatments. Curr Opin Neurol 2010; 23(5): 524–529.
Bellini M, e.a. Gastrointestinal manifestations in myotonic muscular dystrophy. World J Gastroent 2006; 12(12): 1821–1828.
Bianchi ML. Osteoporosis in children and adolescents. Bone 2007; 41(4): 486–495.
Bianchi ML, e.a. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment. Osteop Int 2011; 22(2): 529–539.
Blondet A, e.a. Radiologic versus endoscopic placement of percutaneous gastro-stomy in amyotrophic lateral sclerosis: multivariate analysis of tolerance, efficacy, and survival. J Vasc Intervent Radiol 2010; 21(4): 527–533.
Borrelli O, e.a. Evolution of gastric electrical features and gastric emptying in children with Duchenne and Becker muscular dystrophy. Am J Gastroent 2005; 100(3): 695–702.
Bosboom WM, e.a. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database of systematic reviews, 2009.
Bouteloup C, e.a. Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol 2009: 256(8): 1236–1242.
Burns J, e.a. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009; 8(6): 537–544.
Bushby K, e.a. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010a; 9(1): 77–93.
Bushby K, e.a. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010b; 9(2): 177–189.
Cano NJM, e.a. Nutritional depletion in patients on long-term oxygen therapy and/or home mechanical ventilation. Eur Resp J 2002; 20(1): 30–37.
Chinnery P, e.a. Treatment for mitochondrial diseases. Cochrane Database of systematic reviews, 2006.
Chung YL, e.a. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism 2007; 57(4): 694–702.
Coyle K, e.a. Metabolic abnormalities and cardiovascular risk factors in children with myositis. J Pediat 2009; 155(6): 882–887.
Desport JC, e.a. Validation of bioelectrical impedance analysis in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 2003; 77(5): 1179–1185.
Dupuis L, e.a. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurol 2008; 70(13): 1004–1009.
Dupuis L, e.a. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 2011; 10(1): 75–82.
Engel-Hoek L van den, e.a. Dysphagia in spinal muscular atrophy type II: more than a bulbar problem? Neurol 2009; 73(21): 1787–1791.
Escolar DM, e.a. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 2005;58: 151–155.
Finsterer J. Cardiopulmonary support in Duchenne muscular dystrophy. Lung 2006; 184: 205–215.
Gawne AC, Wells KR, Wilson KS. Cardiac risk factors in polio survivors. Arch Phys Med Rehab 2003; 84(5): 694–696.
Gonzalez-Bermejo J, e.a. Resting energy expenditure in Duchenne patients using home mechanical ventilation. Eur Resp J 2005; 25(4): 682–687.
Graf M, e.a. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Trans 2005; 112(5): 649–660.
Jennekens FGI, e.a. (red.). Myotone dystrofie, begeleiding en behandeling. Maarssen: Elsevier Gezondheidszorg, 2000.
Kearney M, e.a. Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database of systematic reviews, 2009.
Khatri IA, e.a. Low bone mineral density in spinal muscular atrophy. J Clin Neuromusc D 2008; 10(1): 11–17.
Kilmer DD, Wright NC, Aitkens S. Impact of a home-based activity and dietary interventions in people with slow progressive neuromuscular diseases. Arch Phys Med Rehab 2005; 86(11): 2150–2156.
Kinali M, e.a. Bone mineral density in a paediatric spinal muscular atrophy population. Neuropediatrics 2004; 35(6): 325–328.
Limousin N, e.a. Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS. J Neurol Scien 2010; 297(1-2): 36–39.
Lunshof L, Schweizer JJ. Acute maagdilatatie bij de ziekte van Duchenne. NTVG 2000; 144(46): 2214–2217.
Martigne L, e.a. Efficacy and tolerance of gastrostomy feeding in Duchenne muscular dystrophy. Clin Nutr 2010; 29(1): 60–64.
Matsumura T, e.a. A cross-sectional study for glucose intolerance of myotonic dystrophy. J Neurol Scien 2009; 276(1-2): 60–65.
Micallef J, e.a. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A; a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009; 8(12): 1103–1110.
Miller RG, e.a. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews, 2007.
Miller RG, e.a. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurol 2009; 73(15): 1218–1226.
Mok E, e.a. Estimating body composition in children with Duchenne muscular dystrophy: comparison of bioelectrical impedance analysis and skinfold-thickness measurement. Am J Clin Nutr 2006; 83(1): 65–69.
Motlagh B, MacDonald JR, Tarnopolsky MA. Nutritional inadequacy in adults with muscular dystrophy. Muscle & Nerve 2005; 31(6): 713–718.
Moxley RT, e.a. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010; 25(9): 1116–1129.
Muris JWM, Mathus-Vliegen EMH, Voorn ThB (red.). Gastro-enterologie. Houten: Bohn Stafleu van Loghum, 2007.
Nefussy B, e.a. Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis. J Neurol Scien 2011; 300(1-2): 23–27.
ørngreen MC, e.a. Patients with severe muscle wasting are prone to develop hypoglycemia during fasting. Neurol 2003; 61(7): 997–1000.
Park JH, Kang SW. Percutaneous radiologic gastrostomy in patients with amyotrophic lateral sclerosis on noninvasive ventilation. Arch Phys Med Rehab 2009; 90(6): 1026–1029.
Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews, 2010.
Quinlivan R, e.a. Report of a muscular dystrophy campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neurom Dis 2005; 15: 72–79.
Quinlivan R, Beynon RJ, Martinuzzi A. Pharmocological and nutritional treatment for McArdle disease (Glycogen storage disease type V). Cochrane Database of Systematic Reviews, 2008.
Rakocevic Stojanovic V, e.a. Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. Acta Neurol Scan 2010; 121(2): 94–98.
Ramelli GP, e.a. Gastrostomy placement in paediatric patients with neuromuscular disorders: indications and outcome. Dev Med Child Neurol 2007; 49(5): 267–271.
Revalidatiegeneeskundige Richtlijn Ataxie van Friedreich. Vereniging Spierziekten Nederland. Baarn: Kwaliteitsinstituut voor de Gezondheidszorg CBO, 2003.
Richtlijn decubitus, tweede herziening. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Utrecht, 2002.
Richtlijn Guillain-Barré syndroom. Vereniging Spierziekten Nederland, Nederlandse Vereniging voor Neurologie, Nederlandse Vereniging van Revalidatieartsen. Utrecht: Kwaliteitsinstituut voor de Gezondheidszorg CBO, 2010. Bij www.​vsn.​nl webwinkel te koop in boekvorm en downloadbaar.
Richtlijn Osteoporose en fractuurpreventie, derde herziening. Utrecht: Kwaliteits-instituut voor de Gezondheidszorg CBO, concept 2010.
Samson M, Gooszen HG. Behandeling bij ernstig vertraagde maaglediging. NTVG 2000; 144 (41): 1945–1948.
Santiago RA, e.a. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scan J Rheum 2008; 37(1): 40–47.
Schulz JB, Di Prospero NA, Fischbeck K. Clinical experience with high-dose Idebenone in Freidreich ataxia. J Neurol 2009; 256(Suppl 1): 42–45.
Shieh K, Gilchrist JM, Promrat K. Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy. Muscle & Nerve 2010; 41(2): 197–201.
Stanghellini V e.a. Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroent Mot 2007; 19(6): 440–452.
Straathof CS, e.a. Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy. J Neurol 2009; 256(5): 768–773.
Tarnopolsky M, e.a. Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type1. Muscle & Nerve 2004, 29: 51–58.
Tarnopolsky MA, e.a. Bacterial overgrowth syndrome in myotonic muscular dystrophy is potentially treatable. Muscle & Nerve 2010; 42: 853–855.
Terzi N, e.a. Breathing-swallowing interaction in neuromuscular patients: a physiological evaluation. Am J Resp Crit Care Med 2007; 175(3): 269–276.
Vaisman N, e.a. Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Scien 2009; 279(1-2): 26–29.
Veldink JH, e.a. Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psych 2007; 78: 367–371.
Wang CH, e.a. Consensus statement for standard of care in spinal muscular atrophy. J Child Neur 2007; 22(8): 1027–1049
Zanardi MC, e.a. Body composition and energy expenditure in Duchenne muscular dystrophy. Eur J Clin Nutr 2003; 57(2): 273–278.
Metagegevens
Titel
Voeding bij neuromusculaire aandoeningen
Auteur
J.C. Wijnen
Copyright
2012
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-0508-7_69